Amide chemical exchange saturation transfer at 7 T: a possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients

Table 1 Patient demographics and tumor characteristics

Patient	Age (years)	Treatment regimes	ER	PR	HER2 neu	Diameter (mm)^a	TNM stage
1	61	4×AC–12×paclitaxel	+	–	+	24	T2N1M0
2	50	3×FEC–3×docetaxel	+	+	–	30	T4N1M0
3R	57	3×FEC–3×docetaxel	+	+	–	35	T2N0M0
3L	57	3×FEC–3×docetaxel	+	+	–	15	T1N0M0
4	43	3×FEC–3×docetaxel	+	–	–	24	T2N0M0
5	59	3×FEC–3×docetaxel	+	+	–	32	T2N1M0
6	39	3×FEC–3×docetaxel	+	–	–	110	T3N2M0
7	55	6×Taxotere–AC	–	–	–	32	T2N0Mx
8	63	6×Taxotere–AC	+	+	–	15	T2N1Mx
9	35	6×Taxotere–AC	–	–	–	30	T2N0M0

AC adriamycin and cyclophosphamide, ER estrogen receptor, FEC 5-fluorouracil, epirubicin, and cyclophosphamide, HER2 human epidermal growth factor receptor 2, L left, PR progesterone receptor, R right, TNM tumor, nodes, metastasis (classification of malignant tumors)
^a Measurement performed on 3 T magnetic resonance imaging acquired for standard clinical practice

ISSN: 1465-542X